OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that the first patient has been treated in KEYNOTE-890, a Phase 2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical TrialNovember 7, 2018 8:00 AM Pre-Open Movers 11/06: (VCEL) (ELF) (MYL) Higher; (ONCS) (FTDR) (RL) Lower (more...)November 6, 2018 9:24 AM Oncosec Medical (ONCS) KEYNOTE-695 Phase 2b Data Shows Partial Response in Two of Nine Patients, One Had Stable DiseaseNovember 6, 2018 8:07 AM